On April 15, 2025, Dermata Therapeutics announced positive topline results from its Phase 3 trial of XYNGARI for treating moderate-to-severe acne, showing significant efficacy compared to placebo after four weeks. The results indicated a 11.9% treatment success rate for XYNGARI versus 6.2% for placebo, with significant reductions in inflammatory and non-inflammatory lesions.